Commentary

Article

State of the Science Summit: Gynecologic Cancers - Chaired By Robert DeBernardo, MD

In Partnership With:

State of the Science Summit: Gynecologic Cancers - Chaired By Robert DeBernardo, MD

State of the Science Summit: Gynecologic Cancers - Chaired By Robert DeBernardo, MD

Interested in virtually attending an IPC event? Click here to register for an upcoming webinar.

Some of the episodes from our podcast, OncLive On Air, are focused on the interviews with faculty conducted at the State of the Science Summits. Click here to listen to our latest episodes!

Related Videos
Moshe Ornstein, MD, MA, medical oncologist, Department of Hematology and Medical Oncology, Cleveland Clinic
Matthew Powell, MD
Laura J. Chambers, DO
Shannon N. Westin, MD, MPH, FACOG, director, Early Drug Development, clinical medical director, professor, Department of Gynecologic Oncology and Reproductive Medicine, Division of Surgery, codirector, Ovarian Cancer Moonshot Program, The University of Texas MD Anderson Cancer Center
Long-term Follow-up of Selinexor Maintenance for Patients With TP53wt Advanced or Recurrent Endometrial Cancer: A Prespecified Subgroup Analysis From the Phase 3 ENGOT-EN5/GOG-3055/SIENDO Study
Maurie Markman, MD
Salman R. Punekar, MD
Bhavana Pothuri, MD
David M. O’Malley, MD
Allison Winter, MD
Related Content
Anna Dańska-Bidzińska, MD, a gynecologist from Warsaw Medical University in Warsaw, Poland
September 18th 2024

Lenvatinib Plus Pembrolizumab Affords Deep and Durable Responses in Endometrial Cancer

OncLive On Air
September 11th 2024

Oncology Experts Preview Top Abstracts From the 2024 ESMO Congress

FDA
September 16th 2024

FDA Lifts Partial Clinical Hold on Trials Evaluating Azenosertib in Advanced Solid Tumors

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

Shibani Nicum, BSc (Hons), MBChB, MRCP, DPhil
September 15th 2024

Olaparib/Cediranib Misses Survival End Points in Relapsed Ovarian Cancer Trial

Domenica Lorusso, MD, PhD
September 14th 2024

KEYNOTE-A18 Data Support Pembrolizumab Plus Chemoradiotherapy as New SOC in High-Risk Locally Advanced Cervical Cancer